Denise Connolly

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi Pathology of Ovarian Neoplasms in Genetically Modified Mice
    Alexander Y Nikitin
    Department of Biomedical Sciences, Cornell University, T2 014A VRT, Campus Road, Ithaca, New York 14853
    Comp Med 54:26-8. 2004
  2. ncbi Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo
    Rafael Pieretti-Vanmarcke
    Pediatric Surgical Research Laboratories, Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 12:1593-8. 2006
  3. ncbi Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer
    Rafael Pieretti-Vanmarcke
    Pediatric Surgical Research Laboratories, Department of Surgery, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 103:17426-31. 2006
  4. ncbi Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer
    Denise C Connolly
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:1389-97. 2003
  5. ncbi Activation of cancer-specific gene expression by the survivin promoter
    Rudi Bao
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 94:522-8. 2002
  6. ncbi Focus on epithelial ovarian cancer
    Robert F Ozols
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Cell 5:19-24. 2004
  7. ncbi Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer
    Takiko Daikoku
    Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Cancer Res 66:2527-31. 2006
  8. ncbi RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer
    Seiji Mabuchi
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 67:2408-13. 2007
  9. ncbi Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer
    HARVEY HENSLEY
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1717-25. 2007

Research Grants

  1. The Role of HEF1 in Ovarian Cancer Development, Progression, and Metastasis
    Denise C Connolly; Fiscal Year: 2010

Collaborators

Detail Information

Publications9

  1. ncbi Pathology of Ovarian Neoplasms in Genetically Modified Mice
    Alexander Y Nikitin
    Department of Biomedical Sciences, Cornell University, T2 014A VRT, Campus Road, Ithaca, New York 14853
    Comp Med 54:26-8. 2004
  2. ncbi Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo
    Rafael Pieretti-Vanmarcke
    Pediatric Surgical Research Laboratories, Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 12:1593-8. 2006
    ..We examined whether rhMIS as a novel, nontoxic, naturally occurring growth inhibitor can be an effective anticancer drug in long-term studies in vivo against allograft tumors that recapitulate human ovarian carcinoma...
  3. ncbi Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer
    Rafael Pieretti-Vanmarcke
    Pediatric Surgical Research Laboratories, Department of Surgery, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 103:17426-31. 2006
    ..These assays and statistical analyses could be useful in selecting rhMIS and chemotherapeutic agent combinations that enhance clinical efficacy and reduce toxicity...
  4. ncbi Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer
    Denise C Connolly
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 63:1389-97. 2003
    ....
  5. ncbi Activation of cancer-specific gene expression by the survivin promoter
    Rudi Bao
    Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 94:522-8. 2002
    ..Thus, the survivin promoter may be useful in controlling gene expression in cancer cells...
  6. ncbi Focus on epithelial ovarian cancer
    Robert F Ozols
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Cancer Cell 5:19-24. 2004
  7. ncbi Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer
    Takiko Daikoku
    Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Cancer Res 66:2527-31. 2006
    ..The results provide further evidence that Cox-1 overexpression is common in various models of EOC. Thus, Cox-1 serves as a potential marker of EOC and is a possible target for the prevention and/or treatment of this deadly disease...
  8. ncbi RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer
    Seiji Mabuchi
    Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Res 67:2408-13. 2007
    ....
  9. ncbi Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer
    HARVEY HENSLEY
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer Biol Ther 6:1717-25. 2007
    ..Our results demonstrate that MRI is well tolerated and can be repeated in serial imaging studies, permitting quantitative analysis of tumor growth and progression and response to therapeutic interventions...

Research Grants2

  1. The Role of HEF1 in Ovarian Cancer Development, Progression, and Metastasis
    Denise C Connolly; Fiscal Year: 2010
    ..These studies may reveal several important molecular pathways regulated by HEF1 that can be targeted for treatment of ovarian cancer patients. ..